Carl Borrebaeck brings experience from his time as a Board member of Immunovia AB, SenzaGen AB, CB Ocean Capital AB, Alligator Bioscience AB, Clinical Laserthermia Systems AB, Scandion A/S, and commercial
In an in-vivo study involving 16 New Zeeland White rabbits Xlucane (ranibizumab (Lucentis) biosimilar) demonstrated equivalent tolerability and pharmacokinetic profile in the serum and in the vitreous body compared to
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
Nordic Life Science
The latest clinical trials
Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo at the 23rd Congress of The European Hematology Association (EHA). The updated phase II-data show a clinical data
AstraZeneca and Eli Lilly and Company are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease.
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for
H. Lundbeck A/S and Takeda Pharmaceutical announce positive results from their pivotal study with vortioxetine in adults with Major Depressive Disorder conducted in Japan. Both companies intend to move forward
Lundbeck and Otsuka Pharmaceutical announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on Rxulti (brexpiprazole) for
The company has anounced results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1
The two pharma giants reports data which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of
The Phase 2b trial with Betalutin (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional Committees for Medical and Health Research Ethics (REK) in Norway.
The trial, the second of two pivotal Phase III trials for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), did not meet the primary endpoint of
The latest research news from the Nordic region
Scientists at Karolinska Institutet have discovered that one of the building blocks in the calcium channels in the pancreatic beta cells play an important role in regulating our blood glucose
He gets the prize for developing novel microscopy techniques and methods to improve the ability to obtain information from biological specimens. Thomas Deerinck is a research scientist, technical specialist and
The President of Karolinska Institutet has made the decision to find seven researchers responsible for scientific misconduct in the Macchiarini case. The case concerns six articles published in the scientific
Xiaowei Zhuang’s microscopy method, STORM, has revolutionized life sciences and enabled breakthrough discoveries, and for this work she was awarded the Lennart Nilsson Award 2017. Xiaowei Zhuang, the David B. Arnold Professor of Science at Harvard University and a Howard Hughes Medical Institute Investigator, developed one of the first single-molecule imaging methods to break the diffraction limit, i.e. an optical effect that limits the resolution of conventional light microscopes to a few hundred
A new study from Karolinska Institutet and the University of Helsinki show that therapeutic use of gene editing with the CRISPR-Cas9 technique may inadvertently increase the risk of cancer. Two
A network for the promotion of research and education in microfluidics was recently launched at a conference at SciLifeLab. Microfluidics is a research area that deals with fluids on the